Loading clinical trials...
Loading clinical trials...
Effect of Topical Aqueous Suppressants on Response to Intravitreal Anti-vascular Endothelial Growth Factor Injections in Age-related Macular Degeneration (AMD), Retinal Vein Occlusions (RVO) or Diabetic Macular Edema (DME).
Conditions
Interventions
Dorzolamide-timolol
Locations
1
United States
Wills Eye Hospital / Mid Atlantic Retina
Philadelphia, Pennsylvania, United States
Start Date
February 1, 2015
Primary Completion Date
September 30, 2015
Completion Date
December 20, 2015
Last Updated
December 3, 2019
NCT05913063
NCT07449936
NCT07449923
NCT06990269
NCT06970665
NCT07160179
Lead Sponsor
Wills Eye
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions